

Specific inhibition of binding of antistasin and [A^{103,106,108}] antistasin 93–119 to sulfatide (Gal(3-SO₄)β1-1Cer) by glycosaminoglycans

Robert G. Brankamp¹, George D. Manley¹, Thomas J. Owen¹, John L. Krstenansky² and Alan D. Cardin¹

¹Marion Merrell Dow Research Institute, 2110 East Galbraith Rd, Cincinnati, OH 45215, USA and ²Syntex Research, 3401 Hillview Ave., Palo Alto, CA 94303, USA

Received 5 November 1991

Leech-derived antistasin is a potent anticoagulant and antimetastatic protein that binds sulfatide (Gal(3-SO₄)β1-1Cer) and sulfated polysaccharides. In this study, the synthetic fragment [A^{103,106,108}] antistasin 93–119, which corresponds to the carboxyl terminus, showed specific and saturable binding to sulfatide. Binding was competitively blocked by glycosaminoglycans (GAGs) in the order: dextran sulfate 5000 > dextran sulfate 500 000 > heparin > dermatan sulfate >> chondroitin sulfates A and C. This rank order of inhibitory potency was identical to that observed with whole antistasin. We suggest that residues 93–119 of antistasin represent a critical domain for binding GAGs and sulfated glycolipids.

Antistasin; Ghilanten; *Haementeria*; Sulfatide; Glycosaminoglycans; Leech

1. INTRODUCTION

Antistasin is a 119-amino acid leech protein from *Haementeria officinalis* [1]. This protein, and a similar one from *Haementeria ghilianii* [2], inhibit the blood clotting enzyme Factor Xa. These inhibitors contain a 2-fold internal repeated homology [3,4]. The amino-terminal domain contains the inhibitory residues that block the catalytic site of Factor Xa [3,4]. The carboxyl-terminal half contains a basic amino acid-rich tail that fits a consensus motif for binding glycosaminoglycans (GAGs) [5]. At present, the domain(s) that mediates the specific interactions of antistasin with GAGs and sulfated glycolipids remains to be determined. In this study, we demonstrate that [A^{103,106,108}] antistasin 93–119 mimics the interaction of whole antistasin with sulfatide and sulfated polysaccharides.

2. EXPERIMENTAL

[A^{103,106,108}] antistasin 93–119 was synthesized as recently described [6] in which alanine for cysteine substitutions were made at positions 103, 106 and 108 in order to prevent covalent aggregation during purification. Peptides purity was established by analytical high performance liquid chromatography, quantitative amino acid analysis [7] and fast atom bombardment mass spectrometry. Antistasin was purified from fresh salivary glands from *Haementeria officinalis* as described in [1] and purity was established as described in [2]. Antistasin and [A^{103,106,108}] antistasin 93–119 (50 µg) were radiolabeled with Na¹²⁵I (17 Ci/mmol, Amersham-Searle, Arlington Heights, IL) using

the chloramine-T method [8]. The reaction mixture was desalted on a Bio Gel P-2 column equilibrated in phosphate buffered saline, pH 7.4 (PBS); 0.5 ml fractions were collected in teflon coated tubes containing 100 µl of PBS and 6 mg/ml BSA. The labeled samples were stored at –80°C and a fresh tube thawed for each experiment.

The wells of Immulon 4 Removawell polystyrene microtitre plates (Dynatech Laboratories, Inc., Chantilly, VA) were coated with 200 µl of 100 µg/ml Gal(3-SO₄)β1-Cer (sulfatide; Sigma, St. Louis, MO) in methanol. The solvent was evaporated with nitrogen and the plate subjected to high vacuum for 20–30 min. Wells were blocked for 2 h with 250 µl of 1% bovine serum albumin (BSA) in standard buffer (10 mM HEPES, 0.15 M NaCl, pH 7.4), aspirated and washed 4-times. Next, increasing amounts of ¹²⁵I-labeled antistasin or ¹²⁵I-labeled [A^{103,106,108}] antistasin 93–119 were added. After 3–4 h at room temperature the wells were aspirated and washed as above. ¹²⁵I-labeled antistasin and ¹²⁵I-labeled [A^{103,106,108}] antistasin 93–119 bound to sulfatide were then determined by gamma counting. For competition studies, increasing amounts of GAGs were added, followed by a constant amount of ¹²⁵I-labeled [A^{103,106,108}] antistasin 93–119 or ¹²⁵I-labeled antistasin. The wells were incubated and washed as described above until the counts in the wash were near to background. The amount of peptide bound to sulfatide was determined by gamma counting.

Heparin binding was assessed by adding increasing amounts of ¹²⁵I-labeled [A^{103,106,108}] antistasin 93–119 to Eppendorf tubes containing 100 µl of heparin agarose (Bethesda Research Laboratories Life Technologies Inc., Gaithersburg, MD) in a final volume of 250 µl of 50 mM HEPES, 0.1 M NaCl, pH 7.4. The tubes were incubated for 5 min at room temperature, centrifuged and counts in the supernatant were determined.

3. RESULTS AND DISCUSSION

Fig. 1 shows that the binding of ¹²⁵I-labeled [A^{103,106,108}] antistasin 93–119 to Gal(3-SO₄)β1-1Cer was saturable and specific as negligible binding occurred in the absence of sulfatide. As shown, this peptide contains

Correspondence address: A.D. Cardin, Marion Merrell Dow Research Institute, 2110 East Galbraith Rd., Cincinnati, OH 45215, USA. Fax: (1) (513) 948 6204.




Fig. 1. The binding of ^{125}I -labeled $[\text{A}^{103,106,108}]$ antistasin 93-119 to sulfatide. Microtiter wells were coated (■) or not coated (●) with sulfatide.

2 basic-rich amino acid regions (underlined) that potentially mediate antistasin's interaction with sulfated glycolipids and GAGs. Radioiodination occurred at Tyr-105, 3 and 4 residues removed from these domains.

Fig. 2 shows that the binding of ^{125}I -labeled $[\text{A}^{103,106,108}]$ antistasin 93-119 to heparin agarose was specific for the GAG as unlabeled heparin caused its release into the supernatant. Thus, Figs. 1 and 2 demonstrate that $[\text{A}^{103,106,108}]$ antistasin 93-119 binds both to sulfatide and heparin. As GAGs are known to block the antistasin-sulfatide interaction [9] the relative ability of various sulfated polysaccharides to block the binding of $[\text{A}^{103,106,108}]$ antistasin 93-119 to $\text{Gal}(3\text{-SO}_4)\beta 1\text{-Cer}$ was examined. The results of a representative experiment are shown in Fig. 3 and the data from 4 such experiments are summarized in Table I. The relative order of the inhibitory potencies (dextran sulfate 5000 = dextran sulfate 500000 > heparin > dermatan sulfate > chondroitin sulfates A and C) and their ratios (dextran sulfate: heparin and dextran sulfate: dermatan sulfate) were nearly identical to those reported to block the




Fig. 2. The binding of ^{125}I -labeled $[\text{A}^{103,106,108}]$ antistasin 93-119 to heparin agarose in the absence (■) and presence (●) of 10 mg/ml heparin.




Fig. 3. The effect of various glycosaminoglycans on the binding of $[\text{A}^{103,106,108}]$ antistasin 93-119 to $\text{Gal}(3\text{-SO}_4)\beta 1\text{-Cer}$. Dextran sulfate 5000 (◆); dextran sulfate 500 000 (▲); heparin (●); dermatan sulfate (△); chondroitin sulfates A (■) and C (○).

binding of antistasin to sulfatide [9] and ^{125}I -labeled heparin binding to $[\text{A}^{103,106,108}]$ antistasin 93-119 [6]. Thus antistasin and its carboxyl-terminal tail (residues 93-119) show the same quantitative relationships between their GAG and sulfatide binding properties. The relative abilities of dextran sulfate, heparin and dermatan sulfate to suppress the binding of antistasin to sulfatide are shown in Fig. 4. Dextran sulfate and heparin were considerably more potent than dermatan sulfate, whilst chondroitin sulfates A and C (not shown) were inactive at all concentrations tested.

In summary, this study demonstrates that residues 93-119 of antistasin mimics the interaction of antistasin with sulfatide and sulfated polysaccharides. Site-directed mutational studies should clarify further the functional role of this domain in the *in vivo* anticoag-

Table I

Effect of sulfated polysaccharides on the binding of ^{125}I -labeled $[\text{A}^{103,106,108}]$ antistasin 93-119 to sulfatide

GAG	IC_{50} ($\mu\text{g/ml}$) ^a	
	Peptide*/sulfatide ^b	Heparin**/peptide ^c
Heparin	90 (16)	(100)
Dextran sulfate 5000	8 (1.4)	(7)
Dextran sulfate 500 000	9 (1.5)	(8)
Dermatan sulfate	950 (195)	(1000)
Chondroitin sulfate A	>1000 (>500)	(>1000)
Chondroitin sulfate C	>1000 (>500)	(>1000)

^a Concentration of GAG giving 50% inhibition of binding.

^b Values in parentheses reported by Holt et al. [9] for whole antistasin binding to sulfatide.

^c Data in parentheses are those of Manley et al. [6].

* Indicates radioiodinated $[\text{A}^{103,106,108}]$ antistasin 93-119 bound to $\text{Gal}(3\text{-SO}_4)\beta 1\text{-Cer}$ that is displaced by the various GAGs.

** Indicates radioiodinated heparin bound to $[\text{A}^{103,106,108}]$ antistasin 93-119 that is displaced by the various GAGs.




Fig. 4. The effect of various glycosaminoglycans on the binding of ¹²⁵I-labeled whole antistasin to sulfatide. Solid bar, control (no competitor added); striped bar, dextran sulfate 5000; cross-hatched bar, heparin; open bar, dermatan sulfate. No inhibition was observed with chondroitin sulfates A and C at 1 mg/ml.

ulant, antimetastatic and pharmacokinetic behaviour of the inhibitor.

Acknowledgements: We thank Ms. Mary Lynn Points for the preparation of this manuscript. We also thank Dr. David Sarabia Orosio

(Laboratoria de Helminthologia, Dept. de Zoología del Instituto de Biología de la Universidad Nacional Autónoma de México) for the identification and collection of the leech *Haementeria officinalis*. We also thank Dr. Don Klemm USA Environmental Protection Agency) for his suggestions regarding this work.

REFERENCES

- [1] Tuszynski, G.P., Gasic, T.B. and Gasic, G.J. (1987) *J. Biol. Chem.* 262, 9718-9723.
- [2] Brankamp, R.G., Blankenship, D.T., Sunkara, P.S. and Cardin, A.D. (1990) *J. Lab. Clin. Med.* 115, 89-97.
- [3] Nutt, E., Gasic, T., Rodkey, J., Gasic, G.J., Jacobs, J.W., Friedman, P.A. and Simpson, E. (1988) *J. Biol. Chem.* 263, 10162-10167.
- [4] Blankenship, D.T., Brankamp, R.G., Manley, G.D. and Cardin, A.D. (1990) *Biochem. Biophys. Res. Commun.* 166, 1384-1389.
- [5] Jackson, R.L., Busch, S.J. and Cardin, A.D. (1991) *Physiol. Rev.* 71, 481-539.
- [6] Manley, G.D., Owen, T.J., Krstenansky, J.L., Brankamp, R.G. and Cardin, A.D. (1991) *Heparin and Related Polysaccharides*, Plenum Press, (in press).
- [7] Blankenship, D.T., Krivanek, M.A., Ackermann, B.L. and Cardin, A.D. (1989) *Anal. Biochem.* 178, 227-232.
- [8] Greenwood, F.C., Hunter, W.H. and Glover, J.S. (1963) *J. Biochem.* 89, 114-123.
- [9] Holt, G.D., Krivan, H.C., Gasic, G.J. and Ginsburg, V. (1989) *J. Biol. Chem.* 264, 12138-12140.